巨頭賽默飛104億歐元收購凱杰

2020/3/9 10:52:36

2020年3月3日-全球科學服務領域的領軍企業(yè)賽默飛世爾(紐約證券交易所：TMO)與全球分子診斷和樣品制備技術提供商QIAGEN NV(紐約證券交易所：QGEN;法蘭克福證券交易所：QIA)宣布，雙方董事會已一致通過了賽默飛世爾以每股39歐元現(xiàn)金收購QIAGEN的提議。

QIAGEN的要約價格比交易宣布前的最后一個交易日（2020年3月2日）收盤價溢價約23%。賽默飛世爾將收購QIAGEN的所有普通股。
以當前匯率計算，這筆交易對QIAGEN的估值約為115億美元，其中包括承擔約14億美元凈債務的假設。
賽默飛世爾科技董事長，總裁兼首席執(zhí)行官Marc N. Casper表示：“我們很高興能夠補充產品組合，以推進客戶從發(fā)現(xiàn)到診斷的重要工作。此次收購為我們提供了利用我們行業(yè)領先的能力和研發(fā)專業(yè)知識的機會，來加速創(chuàng)新并滿足新興醫(yī)療需求。對于股東而言，我們希望交易能夠立即帶來效果，并產生巨大的成本和收入協(xié)同效應。”
QIAGEN是生命科學和分子診斷解決方案的領先提供商，在25個國家/地區(qū)的35個地點擁有約5100名員工。該公司2019年的收入為15.3億美元。它的樣品制備技術用于從多種生物樣品中提取、分離和純化DNA、RNA和蛋白質。該公司的檢測技術被用于擴增和富集這些生物分子，以使其易于進行分析。此外，QIAGEN儀器可用于自動化工作流程，而其生物信息學系統(tǒng)可為客戶提供高可行性的解決方案。
QIAGEN N.V.臨時首席執(zhí)行官兼分子診斷業(yè)務領域主管高級副總裁Thierry Bernard說：“我們在QIAGEN的愿景一直是通過我們獨特的Sample to Insight分子測試解決方案來改善生活。與賽默飛世爾的戰(zhàn)略合作將使我們進入一個充滿希望的新時代，并為我們的員工提供機會，發(fā)揮更大的影響。合并的目的是為股東帶來可觀的現(xiàn)金價值，同時使我們能夠加快解決方案的擴展，為全球客戶提供突破性的突破，從而增強我們對生命科學的認識并改善健康狀況?！?/span>
Casper總結說：“我們期待歡迎QIAGEN的員工加入賽默飛世爾，我們?yōu)橥ㄟ^新的分子診斷技術和改進的生命科學工作流程而推動精密醫(yī)學發(fā)展所帶來的新機遇感到非常興奮?！?/span>

 

 

原文：

WALTHAM, Mass. and VENLO, The Netherlands – March 3, 2020 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to the closing price of QIAGEN’s common stock on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the transaction. Thermo Fisher will commence a tender offer to acquire all of the ordinary shares of QIAGEN.

The transaction values QIAGEN at approximately $11.5 billion at current exchange rates, which includes the assumption of approximately $1.4 billion of net debt.

“We are excited to bring together our complementary offerings to advance our customers’ important work, from discovery to diagnostics,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “This acquisition provides us with the opportunity to leverage our industry-leading capabilities and R&D expertise to accelerate innovation and address emerging healthcare needs. For shareholders, we expect the transaction to be immediately accretive and to generate significant cost and revenue synergies.”

QIAGEN is a leading provider of life science and molecular diagnostic solutions and employs approximately 5,100 people at 35 locations in more than 25 countries. The company generated 2019 revenue of $1.53 billion. Its sample preparation technologies are used to extract, isolate and purify DNA, RNA and proteins from a wide range of biological samples. The company’s assay technologies are then used to amplify and enrich these biomolecules to make them readily accessible for analysis. In addition, QIAGEN’s instruments can be used to automate these workflows, while its bioinformatics systems provide customers with relevant, actionable insights.

“Our vision at QIAGEN has always been to make improvements in life possible with our differentiated Sample to Insight molecular testing solutions,” said Thierry Bernard, interim chief executive officer of QIAGEN N.V. and senior vice president, head of the molecular diagnostics business area. “This strategic step with Thermo Fisher will enable us to enter a promising new era and will give our employees the opportunity to have an even greater impact. The combination is designed to deliver significant cash value to our shareholders, while enabling us to accelerate the expansion of our solutions to provide customers worldwide with breakthroughs that advance our knowledge about the science of life and improve health outcomes.”

Casper concluded, “We look forward to welcoming QIAGEN’s employees to Thermo Fisher and are excited about the new opportunities we’ll have to advance precision medicine through new molecular diagnostics and improved life sciences workflows.”

https://corporate.qiagen.com/newsroom/press-releases/2020/20200303_thermo_acquires_qiagen?

  資訊來源：QIAGEN官網  轉自：生物36